Health Canada Bans Avastin For Breast Cancer Treatment

Law360, New York (November 29, 2011, 5:03 PM EST) -- Health Canada on Monday suspended its authorization of blockbuster Genentech Inc. drug Avastin for treating breast cancer, citing concerns over its effectiveness and life-threatening risks such as heart attacks.

Canada's public health department found that Avastin does not significantly shrink tumors or extend life expectancy for metastatic breast cancer patients, and that it may cause heart attacks, severe high blood pressure, small tears in the nose, stomach or intestines, and bleeding.

The Canadian department based its decision — which does not impact the use of Avastin...
To view the full article, register now.